A phase II randomized placebo-controlled trial of omega-3 fatty acids for the treatment of acute lung injury.

Abstract

OBJECTIVES Administration of eicosapentaenoic acid and docosahexanoic acid, omega-3 fatty acids in fish oil, has been associated with improved patient outcomes in acute lung injury when studied in a commercial enteral formula. However, fish oil has not been tested independently in acute lung injury. We therefore sought to determine whether enteral fish oil alone would reduce pulmonary and systemic inflammation in patients with acute lung injury. DESIGN Phase II randomized controlled trial. SETTING Five North American medical centers. PATIENTS Mechanically ventilated patients with acute lung injury ≥18 yrs of age. INTERVENTIONS Subjects were randomized to receive enteral fish oil (9.75 g eicosapentaenoic acid and 6.75 g docosahexanoic acid daily) or saline placebo for up to 14 days. MEASUREMENTS AND MAIN RESULTS Bronchoalveolar lavage fluid and blood were collected at baseline (day 0), day 4 ± 1, and day 8 ± 1. The primary end point was bronchoalveolar lavage fluid interleukin-8 levels. Forty-one participants received fish oil and 49 received placebo. Enteral fish oil administration was associated with increased serum eicosapentaenoic acid concentration (p < .0001). However, there was no significant difference in the change in bronchoalveolar lavage fluid interleukin-8 from baseline to day 4 (p = .37) or day 8 (p = .55) between treatment arms. There were no appreciable improvements in other bronchoalveolar lavage fluid or plasma biomarkers in the fish oil group compared with the control group. Similarly, organ failure score, ventilator-free days, intensive care unit-free days, and 60-day mortality did not differ between the groups. CONCLUSIONS Fish oil did not reduce biomarkers of pulmonary or systemic inflammation in patients with acute lung injury, and the results do not support the conduct of a larger clinical trial in this population with this agent. This experimental approach is feasible for proof-of-concept studies evaluating new treatments for acute lung injury.

DOI: 10.1097/CCM.0b013e318218669d
0501001502011201220132014201520162017
Citations per Year

332 Citations

Semantic Scholar estimates that this publication has 332 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Stapleton2011API, title={A phase II randomized placebo-controlled trial of omega-3 fatty acids for the treatment of acute lung injury.}, author={Renee D. Stapleton and Thomas R. Martin and Noel S Weiss and Joseph J. Crowley and Stephanie J Gundel and Avery B Nathens and Saadia R Akhtar and John T. Ruzinski and Ellen S Caldwell and J. R. Curtis and Daren Keith Heyland and Timothy Watkins and Polly E. Parsons and Julie M. Martin and Mark M. Wurfel and Teal S. Hallstrand and Kathryn A Sims and Margaret J Neff}, journal={Critical care medicine}, year={2011}, volume={39 7}, pages={1655-62} }